Actively Recruiting
Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations Using Dual Screening RTDs and FibroScan® Outside Conventional Healthcare Settings
Led by University Hospital, Limoges · Updated on 2025-08-14
2300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a new approach called the SCANVIR program to improve screening and treatment of hepatitis B, C, and HIV among drug users and vulnerable populations who often miss usual healthcare pathways. The study focuses on people who inject drugs (PWIDs) and other marginalized groups in France, aiming to overcome barriers to care and better health outcomes. This observational study explores the feasibility and acceptability of a combined testing and treatment strategy conducted in addiction care centers and non-conventional settings. The study uses a triple screening method involving rapid diagnostic tests (RTDs), FibroScan®, and GeneXpert® technology to detect viral infections simultaneously. This "test, treat, and cure" strategy is offered during dedicated days in addiction care centers and other outreach locations. It includes rapid testing, education on viral transmission prevention, encouragement of hepatitis B vaccination, social support, and immediate treatment for hepatitis C-positive patients. Participants will be assessed from enrollment through the end of their same-day participation. Researchers will evaluate how well the screening approach is accepted and how feasible it is to implement in non-traditional settings. Additional assessments include screening for hepatitis Delta, reinforcing prevention education, evaluating PCR feasibility, providing social support, offering quick treatment to infected individuals, and assessing related health issues such as substance misuse and psychiatric conditions. The study aims to improve access to care and viral hepatitis management among these hard-to-reach groups.
CONDITIONS
Brief Title
Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations, in Non-conventional Structures "Outside the Walls" by Dual Screening Method RTDs and FibroScan®
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult 18 years and older
- Patient visits or is referred to a non-traditional care setting "outside the walls"
- Patient is not opposed to participating in research
You will not qualify if you...
- Under 18 years of age
- Patient is opposed to participating in research
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day of enrollment
Participants undergo simultaneous screening for viral hepatitis B, C, and HIV using dual screening methods including RTDs, FibroScan®, and GeneXpert® in non-conventional care settings.
1 visit (in-person)
Duration - Same day as screening and diagnostic evaluation
Participants receive education to prevent viral transmission, social support, assessment of associated co-morbidities, and access to rapid treatment if tested positive, all conducted during the same day of participation.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Limoges University Hospital
Limoges, France, 87000
Actively Recruiting
Research Team
M
Marilyne DEBETTE-GRATIEN, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here